药物研究动态

　　【摘要】在T2DM的发生发展过程中，胰岛b细胞和a细胞存在结构和数量异常、功能障碍。胰升血糖素样肽(GLP-1)类似物利拉鲁肽可直接改善胰岛b细胞功能、抑制其凋亡和增加其数量，并能作用于胰岛α细胞，不仅能够调节细胞功能，早期应用于T2DM治疗有效改善血糖，降低低血糖发生率，还能带来降低体重、降低SBP的益处，其具有药物经济学优势，是T2DM早期治疗的理想选择。

　　【关键词】糖尿病，2型;利拉鲁肽;胰岛素类似物;胰岛细胞;肠促胰素;药物经济学

　　【Summary】] During the development of type 2 diabetes, there appear anomalies of islet b- and a-cell function, structure and amount. GLP-1 analogue liraglutide can improve b-cell function, decrease b-cell apoptosis, increase b-cell mass, and also regulate α-cell function. For type 2 diabetes treatment, early usage of liraglutide provides better glucose control, lower incidence of hypoglycemia, and more benefits of weight loss, systolic blood pressure reduction, as well as the pharmacoeconomic advantages. Liraglutide is an ideal choice for type 2 diabetes early treatment.

　　【Key words】 type 2 diabetes;liraglutide;islet cells;glucagon;pharmacoeconomics